Researchers at MIT’s Singapore-based enterprise have developed a groundbreaking automated tool that can rapidly scan thousands of biological samples to detect tiny chemical changes in RNA molecules that control how cells grow, adapt to stress, and respond to diseases like cancer and antibiotic-resistant infections. The revolutionary system solves a major problem in medical research by replacing slow, labor-intensive, costly, and hazardous chemical processes with fast, automated profiling using robotic liquid handlers and advanced mass spectrometry techniques. Scientists used the tool to extract and analyze tRNA from over 5,700 genetically modified bacterial strains, generating more than 200,000 data points that revealed previously unknown RNA-modifying enzymes and mapped complex gene regulatory networks crucial for understanding how cells survive and adapt. The tool has already discovered new enzymes and biological patterns that could lead to better drug discovery, more accurate disease diagnostics, and the development of personalized medical treatments for conditions that have been incredibly difficult to treat.
Professor Peter Dedon, the study’s corresponding author, called it a transformative advance in decoding the complex language of RNA modifications that regulate cellular responses to disease and stress. Research scientist Jingjing Sun emphasized that this is the first tool capable of rapidly and quantitatively profiling RNA modifications across thousands of samples, making large-scale epitranscriptomic analysis practical and accessible for the first time in history. The pharmaceutical and biotech industries can now efficiently evaluate how potential drugs affect RNA modifications and cellular behavior, dramatically accelerating the development of targeted therapies. Looking ahead, the team plans to expand the tool’s capabilities to analyze RNA modifications in human cells and tissues, moving beyond microbial models to integrate the platform into clinical research and drive the creation of more effective and personalized treatments for cancer and infectious diseases.
